Granules India Reports Q2 Revenue Growth Over Prior Base of ₹1,297 Crore

Market snapshot: Granules India reported a Q2 revenue update indicating expansion over the prior-year baseline of ₹1,297 crore (as stated in the source alert; current figure of ₹1,560 crore is not independently verified). The company continues to strengthen its finished dosage formulations and CDMO peptide capabilities.

Data Snapshot

• Prior-year Q2 revenue baseline recorded at ₹1,297 crore
• Full-year FY26 consolidated revenue reached ₹5,338.92 crore, up 19.81% YoY
• Q3 FY26 revenue stood at ₹1,476.77 crore with operating profit of ₹338.90 crore

What's Changed

• Revenue base expanded from prior-year Q2 level of ₹1,297 crore
• Consolidated annual revenues grew to ₹5,338.92 crore in FY26 from ₹4,455.97 crore in FY25

Key Takeaways

• Granules India shows consistent top-line trajectory supported by finished dosage formulation demand.
• CDMO expansion via peptide capabilities provides strategic multi-year revenue diversification.
• Operating margins benefit from backward integration across APIs and formulation intermediates.

SAHI Perspective

Granules India's ongoing growth reflects successful execution of its formulation-focused strategy and regulatory compliance recovery. Continued ramp-up of higher-margin finished dosages and CDMO offerings helps protect profitability against active pharmaceutical ingredient pricing volatility.

Market Implications

Steady top-line growth reinforces market position among mid-cap pharmaceutical manufacturers. Investors will monitor gross margin trends and operational metrics across North American and European regulated markets.

Trading Signals

Market Bias: Bullish

Granules India demonstrates steady structural growth with full-year FY26 revenue reaching ₹5,338.92 crore and consistent quarterly top-line execution above ₹1,400 crore.

Overweight: Indian Pharmaceuticals, Formulation Exporters

Trigger Factors:

• Regulatory approvals for new ANDA filings in North America
• Ramp-up of peptide CDMO asset utilization
• Quarterly EBITDA margin sustainability above 20%

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian pharmaceutical export sector faces evolving price dynamics in regulated markets, driving players toward value-added formulations, complex generics, and specialized contract development capabilities.

Key Risks to Watch

• Regulatory inspection outcomes and USFDA compliance requirements across manufacturing facilities.
• Fluctuations in key active pharmaceutical ingredient raw material costs and freight rates.
• Pricing pressures in North American generic formulations markets.

Recent Developments

Granules India expanded its specialized active pharmaceutical capabilities by completing the acquisition of Swiss peptide CDMO Senn Chemicals AG (now Ascelis) for ₹192.5 crore.

Closing Insight

Granules India's focus on complex formulation scale and CDMO diversification positions the business for sustainable margin expansion.

High Performance Trading with SAHI.